Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
暂无分享,去创建一个
[1] B. Thiers. Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials , 2007 .
[2] John T. Wei,et al. Laparoscopy for renal cell carcinoma: diffusion versus regionalization? , 2006, The Journal of urology.
[3] F. Wolfe,et al. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. , 2005, The Journal of rheumatology.
[4] Matthias Schneider,et al. Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.
[5] B. Dijkmans,et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.
[6] W. Britton,et al. Independent Protective Effects for Tumor Necrosis Factor and Lymphotoxin Alpha in the Host Response to Listeria monocytogenes Infection , 2005, Infection and Immunity.
[7] C. Turesson,et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.
[8] D. Barlow,et al. Methods of hysterectomy: systematic review and meta-analysis of randomised controlled trials , 2005, BMJ : British Medical Journal.
[9] L. Jacobsson,et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists , 2005, Annals of the rheumatic diseases.
[10] I. Nestorov. Clinical pharmacokinetics of TNF antagonists: how do they differ? , 2005, Seminars in arthritis and rheumatism.
[11] S. Ehlers,et al. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. , 2005, Seminars in arthritis and rheumatism.
[12] S. Gabriel,et al. Cardiovascular death in rheumatoid arthritis: a population-based study. , 2005, Arthritis and rheumatism.
[13] J. Hollander,et al. Trends toward laparoscopic nephrectomy at a community hospital. , 2005, The Journal of urology.
[14] B. Haraoui. Differentiating the efficacy of the tumor necrosis factor inhibitors. , 2005, Seminars in arthritis and rheumatism.
[15] J. Stone. Etanercept plus Standard Therapy for Wegener's Granulomatosis , 2005 .
[16] Alexander Fraser,et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.
[17] L. Klareskog,et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. , 2005, Arthritis and rheumatism.
[18] D. M. van der Heijde,et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.
[19] Silvia Kirchner,et al. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. , 2004, Cytokine.
[20] S. Best,et al. Minimally invasive therapy for renal cell carcinoma: is there a new community standard? , 2004, Urology.
[21] F. Wolfe,et al. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. , 2004, Arthritis and rheumatism.
[22] Alexander J Sutton,et al. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.
[23] E. Keystone,et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.
[24] P. van Riel,et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate , 2004, Scandinavian journal of rheumatology.
[25] M. Dougados,et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed , 2004, Annals of the rheumatic diseases.
[26] R S Wallis,et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] R. Dutton,et al. Effector Cell-Derived Lymphotoxin α and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases , 2004, Cancer Research.
[28] K. Bendtzen,et al. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. , 2004, Clinical and experimental rheumatology.
[29] N. Sato,et al. Human tumor necrosis factor increases the resistance against Listeria infection in mice , 2004, Medical Microbiology and Immunology.
[30] V. Strand,et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.
[31] P. Emery,et al. Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study , 2003, Annals of the rheumatic diseases.
[32] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[33] J. Gómez-Reino,et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.
[34] Klaus Pfeffer,et al. Biological functions of tumor necrosis factor cytokines and their receptors. , 2003, Cytokine & growth factor reviews.
[35] D. Hommes,et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.
[36] H. Paulus,et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. , 2003, Clinical therapeutics.
[37] S. Scheu,et al. The Lymphotoxin β Receptor Is Critically Involved in Controlling Infections with the Intracellular Pathogens Mycobacterium tuberculosis and Listeria monocytogenes1 , 2003, The Journal of Immunology.
[38] A. Widmer,et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. , 2003, Rheumatology.
[39] S. Scheu,et al. The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. , 2003, Journal of immunology.
[40] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[41] L. V. D. van de Putte,et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.
[42] S. Gabriel,et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.
[43] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[44] F. Balkwill. Tumor necrosis factor or tumor promoting factor? , 2002, Cytokine & growth factor reviews.
[45] J. Richert,et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. , 2001, Arthritis and rheumatism.
[46] J. Wolf,et al. Hand-assisted laparoscopic donor nephrectomy: comparable donor/recipient outcomes, costs, and decreased convalescence as compared to open donor nephrectomy. , 2001, Transplantation proceedings.
[47] G. Panayi,et al. Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.
[48] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[49] G. Macfarlane,et al. Risk of malignancy among patients with rheumatic conditions , 2000, International journal of cancer.
[50] I. Olkin,et al. Improving the quality of reports of meta‐analyses of randomised controlled trials: the QUOROM statement , 2000, Revista espanola de salud publica.
[51] R. Clayman,et al. Laparoscopic versus open radical nephrectomy: a 9-year experience. , 2000, The Journal of urology.
[52] P. Lipsky,et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. , 2000, The Journal of rheumatology.
[53] P. Lipsky,et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.
[54] P. Beauparlant,et al. The incidence of cancer associated with the treatment of rheumatoid arthritis. , 1999, Seminars in arthritis and rheumatism.
[55] L. Smeeth,et al. Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading , 1999, BMJ.
[56] G A Colditz,et al. The role of meta-analysis in the regulatory process for foods, drugs, and devices. , 1999, JAMA.
[57] F. Breedveld,et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[58] J. Escarce,et al. Externalities in hospitals and physician adoption of a new surgical technology: an exploratory analysis. , 1996, Journal of health economics.
[59] J. Olsen,et al. Rheumatoid arthritis and cancer risk. , 1996, European journal of cancer.
[60] T. Blankenstein,et al. Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice. , 1995, Blood.
[61] J. Woody,et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.
[62] P. Mastroeni,et al. Effect of late administration of anti-TNF alpha antibodies on a Salmonella infection in the mouse model. , 1993, Microbial pathogenesis.
[63] F. Arnett,et al. Revised criteria for the classification of rheumatoid arthritis. , 1989, Bulletin on the rheumatic diseases.
[64] A. Nakane,et al. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection , 1988, Infection and immunity.
[65] N Breslow,et al. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. , 1986, Biometrics.